EpiEndo Pharmaceuticals

Executive Summary

EpiEndo Pharmaceuticals is a clinical-stage biopharmaceutical company based in Reykjavik, Iceland, focused on developing oral small-molecule therapies for chronic respiratory diseases. Its lead candidate, glasmacinal, is a novel non-antibiotic macrolide designed to treat COPD by enhancing host defense and reducing inflammation without promoting antimicrobial resistance. The company operates as a semi-virtual organization with operations across Iceland, Sweden, Denmark, and the UK. Despite being categorized as preclinical, the company's proprietary platform and unique mechanism of action position it as a potential differentiated player in the respiratory space, addressing the significant unmet need for COPD treatments that avoid the side effects of antibiotics.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 1 Clinical Trial for glasmacinal50% success
• Q3 2026Presentation of preclinical efficacy data at a major respiratory conference70% success
• H2 2026Announcement of strategic partnership or non-dilutive funding40% success